Latest News Archive
Please select Category, Year, and then Month to display items
27 December 2021
|
Story Jóhann Thormählen
|
Photo Supplied
The Kovsie Annerie Dercksen is one of South Africa’s most promising youngsters and climbing the cricketing ladder.
She enjoyed every second of playing with some of her heroes and believes the exposure to international cricket will help her become a better player.
Annerie Dercksen is one of South Africa’s most promising youngsters and climbing the cricketing ladder.
Star from Beaufort West
This second-year Education student from the University of the Free State (UFS), who dreams of playing for the Momentum Proteas, represented the South African Emerging Women’s team three times in 2021.
The star from Beaufort West toured with the side to Bangladesh and also played against Zimbabwe and Thailand in One Day and T20 matches.
According to Dercksen, it is an incredible honour and privilege to be a part of a side.
She soaked up the experience and says everyone was willing to share their knowledge.
“I would have to say, sharing the field with some of my heroes and getting to work with some of the best coaches in the country are some of the highlights.”
She says each tour brought its own challenges and this helped her grow in the way she views and approaches the game.
“In Bangladesh we played against a well-established team in foreign conditions while facing a lot of spinners in spin friendly conditions. Personally, it was quite a challenge and I had to come back and work on some options, especially against spin.”
“Each tour brought its own challenges and this helped me grow in the way I view and approach the game.” - Annerie Dercksen
Coming through the ranks
The all-rounder has come through the ranks. She represented South-Western Districts at school level, played for the South African U19 side and is currently representing the Free State.
But Dercksen didn’t always dream cricket, especially not when playing ‘backyard’ cricket with her brother on the farm.
She didn’t even play for a team at school. “Until a boy from our primary school’s team got sick before a game. A teacher came to class and asked, ‘who can play cricket’, and I put up my hand.”
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004